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What Is an Isoprenoid?
Isoprenoids (also referred to as terpenoids) are the largest group
of natural products, comprising over 25,000 known compounds
[1]. Each member of this class is assembled from 5-carbon (C5)
isoprene units and derived metabolically from the basic building
block isopentenyl pyrophosphate (IPP) and its isomer, dimethy-
lallyl pyrophosphate (DMAPP). Subsequent metabolic reactions
(such as cyclization) generate enormous complexity and diversity
from these basic starting materials. Isoprenoids are vital to all
organismal classes, supporting core cellular functions such as
aerobic respiration (ubiquinones) and membrane stability (choles-
terol) (Figure 1). Isoprenoids also form the largest group of so-
called secondary metabolites, such as the extremely diverse classes
of plant defensive terpenoids that are widely exploited as perfumes,
food additives, and pharmaceutical agents (e.g., the antimalarial
compound artemisinin) [2].
What Is the Non-Mevalonate (MEP) Pathway of
Isoprenoid Biosynthesis?
The basic isoprenoid building blocks (IPP and DMAPP) are
generated in cells by one of two distinct biosynthetic routes. The
classical mevalonate (MVA) pathway was first described in yeast
and mammals in the 1950s [3]. IPP is synthesized from acetyl-CoA
via the key metabolite mevalonate (MVA). The widely used
‘‘statin’’ class of cholesterol-lowering drugs targets the rate-limiting
enzyme of the MVA pathway, HMG-CoA reductase.
By the early 1990s, however, the existence of an alternative
route to IPP had become clear through metabolic labeling studies
in bacteria and plants [4]. This alternate ‘‘non-mevalonate’’
pathway does not share any enzymes or metabolites with the MVA
pathway. It begins by generation of deoxyxyluose 5-phosphate
(DOXP) from pyruvate and glyceraldehyde 3-phosphate. The first
dedicated metabolite of this pathway, methylerythritol 4-phos-
phate (MEP)—from which the pathway derives its name—is then
generated from DOXP by deoxyxylulose phosphate reductoi-
somerase (DXR, also known as IspC). Subsequent enzymatic steps
convert MEP to IPP/DMAPP for synthesis of downstream
isoprenoids. Since the MEP pathway is linear, each of the
enzymes in this pathway is required for de novo isoprenoid
biosynthesis.
Which Microbes Use the MEP Pathway?
The two isoprenoid biosynthetic routes, the mevalonate (MVA)
and non-mevalonate (MEP) pathways, have distinct evolutionary
origins and are phylogenetically compartmentalized [5,6]. Ar-
chaebacteria and most eukaryotes, including all metazoans and
fungi, use the MVA pathway. In contrast, the overwhelming
majority of eubacteria use the MEP pathway, including key
pathogens such as all Gram-negative bacteria and mycobacteria.
Notable exceptions include several clinically important Gram-
positive organisms, including staphylococci and streptococci,
which have retained the MVA pathway, and several obligate
intracellular organisms, including rickettsiae and mycoplasmas,
which have lost de novo isoprenoid metabolism altogether.
While most eukaryotes use the MVA pathway, phyla that have
acquired a plastid organelle (either a true chloroplast, such as in
plants, or a non-photosynthetic relic plastid) possess the eubacte-
ria-like MEP pathway. In microbes, this includes the Apicom-
plexan protozoan pathogens Toxoplasma gondii (which causes
toxoplasmosis) and the malaria-causing Plasmodia species, including
the agent of severe malaria, Plasmodium falciparum. While plants
contain both the MVA and MEP pathways, the Apicomplexans do
not contain the MVA pathway and exclusively generate
isoprenoids via the MEP pathway.
Why Are Isoprenoids Essential in Pathogenic
Microbes?
Isoprenoids are essential in all eubacteria in which they have
been studied [7–9]. Genetic or chemical disruption of enzymes in
this pathway is only possible with a redundant route for isoprenoid
biosynthesis (either media supplementation with isoprenoids or
transgenic expression of the MVA pathway). Isoprenoids are key
to several core bacterial cellular functions. In eubacteria, there are
at least three groups of isoprenoid compounds that appear to be
essential—ubiquinones, menaquinones, and dolichols. Ubiqui-
nones and menaquinones are electron carriers and major
components of the aerobic and anaerobic respiratory chains,
respectively [10]. Dolichols are long-chain, membrane-bound
isoprenols, which are required for cell wall peptidoglycan synthesis
[11]. Agents that block isoprenoid biosynthesis in bacteria
therefore result in spheroplast formation and cell death [12].
The MEP pathway is also clearly essential in Apicoplexan
eukaryotes, including the protozoan malaria parasite P. falciparum
[13–15]. In contrast to eubacteria, it is not as clear why the
malaria parasite needs isoprenoids. The clinical symptoms of
malaria infection arise from the developmental cycle of the
parasite within human erythrocytes. This privileged niche has
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PLoS Pathogens | www.plospathogens.org 1 Month | Volume 7 | Issue 12 | e1002323Figure 1. The non-mevalonate MEP pathway of isoprenoid biosynthesis. Isoprenoids are derived from the basic 5-carbon isoprenoid building
blocks isopentenyl pyrophosphate (IPP) and its isomer, dimethylallyl pyrophosphate (DMAPP). In the MEP pathway, IPP and DMAPP are generated from
pyruvate and glyceraldehyde 3-phosphate. Enzymes of this pathway are named here according to their E. coli homologs (DXR/IspC, IspD, IspE, and IspF).
Fosmidomycin is a phosphonic acid antibiotic (PubChem compound ID 572) that inhibits a rate-limiting enzyme of this pathway (DXR/IspC) and blocks
isoprenoidbiosynthesisinvivo.Isoprenoidshavegreatdiversityinstructureandcellularfunction—fromplasmamembranestability(cholesterol),electron
transport (ubiquinone), and cell wall biosynthesis (dolichols) to protein modification (as prenyl groups) and secondary metabolites (such as artemisinin).
doi:10.1371/journal.ppat.1002323.g001
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essential to eukaryotic membrane stability, the parasite does not
have de novo cholesterol biosynthesis and scavenges membrane
cholesterol from host erythrocyte membranes [16]. The malaria
parasite depends on glycolysis and does not use mitochondrial
respiration for ATP production in the intraerythrocytic cycle [17].
In eukaryotes, dolichols are necessary for protein N-glycosylation,
but P. falciparum produces severely truncated N-glycosyl groups
that may not be required for protein function [18]. Finally, the
malaria parasite makes plant-like signaling molecules (caroten-
oids), but these also do not have a known biological function [19].
The malaria parasite does have well-characterized protein
prenyltransferases, which are expressed during the intraerythro-
cytic cycle [20,21]. Protein prenylation is the isoprenyl modifica-
tion of proteins, such as small GTPases. Either farnesyl (15 carbon)
or geranylgeranyl (20 carbon) groups are attached to C-terminal
cysteines by one of three prenyltransferases. Multiple classes of
prenyltransferase inhibitors kill the malaria parasite, strongly
suggesting that at least protein prenylation is an essential function
of isoprenoid biosynthesis in malaria [20,22].
Why Is the MEP Pathway a Good Antimicrobial
Drug Target?
The MEP pathway has a number of characteristics that make it
a favorable target for antimicrobial drug development. Much like
bacterial cell wall biosynthesis, which has been so successfully
targeted by antibacterial agents, the MEP pathway is essential for
microbial growth, and none of the enzymes of this pathway are
present in mammalian cells. Validation of many of the properties
of a new isoprenoid-inhibitor class of antibiotic has come from
studies of the small phosphonic acid compound fosmidomycin.
Fosmidomycin inhibits DXR (the first dedicated step in the MEP
pathway) in multiple organisms [9,15,23]. It kills E. coli and P.
falciparum, can treat malaria in field trials, and has been validated
as an inhibitor of isoprenoid biosynthesis in vivo [14,24]. Due to its
highly charged structure, it has suboptimal pharmacokinetic
properties, and is also excluded from and non-toxic to several
organisms whose DXR enzyme is otherwise inhibited in vitro by
fosmidomycin (including T. gondii and Mycobacterium tuberculosis)
[9,15]. Despite these challenges, fosmidomycin is currently in
Phase II clinical trials in combination therapy to treat malaria,
because of its favorable safety profile. Very high doses of
fosmidomycin appear to be clinically safe—the oral mouse LD50
is a remarkable .11,000 mg/kg—presumably since there is no
mammalian homolog to be inhibited [25].
Drug resistance has created an urgent need for new antimicro-
bial agents to combat Gram-negative bacteria, M. tuberculosis, and
P. falciparum, which share the MEP pathway. New drugs that
inhibit this pathway hold great promise as broad-spectrum agents,
with potential appeal for commercially viable pharmaceutical
development in the first-world as antibacterial agents (against
resistant hospital-acquired infections, for example) and use in
developing nations in combination therapies for malaria and
tuberculosis.
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